6 completed, 2 unknown, 1 recruiting. 9 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Completed 6, Unknown 2, Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Neoplasms, Unknown Primary: new trials by email Literature Review of Neoplasms, Unknown Primary trials Research Report on Neoplasms, Unknown Primary
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP) F520 combined with chemotherapy, placebo combined with chemotherapy - Cancer of Unknown Primary Site | Phase 2 / Phase 3 | Recruiting | Shandong New Time Pharmaceutical Co., LTD | 402 | 2026-07-08 | 2026-08-12 |
| Postoperative Pain, Why Still in Hospital and DAOH Following TORS for SCCUP & OSAS Dexamethasone, Placebo - Analgesia, Surgery | Phase 3 | Completed | Copenhagen University Hospital, Rigshospitalet | 18 | 2020-08-18 | 2023-03-16 |
| Tissue-of-origin Directing Therapy in Patients With Cancer of Unknown Primary tissue-of-origin (ORIGIN-PanCA○R) profiling - Cancer of Unknown Primary Site | Phase 3 | Completed | Fudan University | 182 | 2017-09-18 | 2022-01-24 |
| Trial Comparing a Strategy Based on Molecular Analysis to the Empiric Strategy in Patients With CUP Cancer Type ID test, No test Empiric strategy - Neoplasms, Unknown Primary | Phase 3 | Completed | Gustave Roussy, Cancer Campus, Grand Paris | 243 | 2012-03-22 | 2020-02-17 |
| Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site Etoposide, Gemcitabine, Irinotecan - Neoplasms, Unknown Primary | Phase 3 | Completed | SCRI Development Innovations, LLC | 198 | 2003-09-01 | 2013-05-03 |
| Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary Tumor radiation therapy - Carcinoma of Unknown Primary | Phase 3 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 600 | 2002-07-01 | 2018-07-09 |
| Combination Chemotherapy in Treating Patients With Metastatic Cancer of an Unknown Site of Origin cisplatin, cyclophosphamide, doxorubicin hydrochloride - Carcinoma of Unknown Primary | Phase 3 | Unknown | The Christie NHS Foundation Trust | 1998-12-01 | 2013-09-20 | |
| Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin carboplatin, etoposide, fluorouracil - Carcinoma of Unknown Primary | Phase 3 | Unknown | Academisch Ziekenhuis Maastricht | 140 | 1998-08-01 | 2013-08-07 |
| Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer mitomycin C, porfiromycin, brachytherapy - Carcinoma of Unknown Primary, Head and Neck Cancer | Phase 3 | Completed | Yale University | 1992-11-01 | 2013-07-25 |
Head and Neck Neoplasms (2) · Agnosia (1) · Oropharyngeal Neoplasms (1) · Pain, Postoperative (1) · Squamous Cell Carcinoma of Head and Neck (1)
Neoplasm Metastasis (9) · Neoplasms (9) · Neoplastic Processes (9) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · Neoplasms by Site (2) · Carcinoma (1) · Carcinoma, Squamous Cell (1) · Neoplasms by Histologic Type (1) · Neoplasms, Glandular and Epithelial (1) · Nervous System Diseases (1) · Neurobehavioral Manifestations (1) · Neurologic Manifestations (1) · Otorhinolaryngologic Diseases (1) · Otorhinolaryngologic Neoplasms (1)
Carboplatin (2) · Etoposide (2) · Fluorouracil (2) · Paclitaxel (2) · Radiotherapy (2) · Albumin-Bound Paclitaxel (1) · Brachytherapy (1) · Cisplatin (1) · Cyclophosphamide (1) · Dexamethasone (1) · Doxorubicin (1) · Drug Therapy (1) · Epirubicin (1) · Gemcitabine (1) · Irinotecan (1)
Academisch Ziekenhuis Maastricht (1) · Copenhagen University Hospital, Rigshospitalet (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Fudan University (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · SCRI Development Innovations, LLC (1) · Shandong New Time Pharmaceutical Co., LTD (1) · The Christie NHS Foundation Trust (1) · Yale University (1)
Denmark (3) · Netherlands (3) · United States (3) · China (2) · Belgium (1) · Canada (1) · France (1) · Switzerland (1) · United Kingdom (1)
Cai Grau, MD (1) · Esat M. Ozsahin, MD, PhD (1) · James J. Fischer, MD, PhD (1) · John D. Hainsworth, MD (1) · Juan W. Valle, MD (1) · R. L. Jansen, MD, PhD (1) · Samy El-Sayed, MD, FFR, FRCR, FRCP (1) · Sharon A. Spencer, MD (1) · Vincent G. Gregoire, MD, PhD (1)